@article{6c21b93643224f3bae6f3b06573ffbb4,
title = "Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas {\`a} cause du BNP?",
author = "Pereira, {Naveen L.} and Desai, {Viral K.} and Jaffe, {Allan S.}",
note = "Funding Information: In conclusion, sacubitril/valsartan therapy in patients with HFrEF resulted in improvement in clinical symptoms, echocardiographic parameters and prognostic biomarkers. The beneficial effects of treatment are likely mediated by ANP and other substances that are substrates for NEP but they are unlikely to be mediated by BNP. Conflict of interest: N.L.P. is supported by National Institute on Aging grant R21AG53512. A.S.J. acknowledges that he consults for most of the major diagnostic companies and Novartis, which makes the drug studied in this report. V.K.D. has no conflicts of interest.",
year = "2019",
month = may,
doi = "10.1002/ejhf.1451",
language = "English (US)",
volume = "21",
pages = "609--612",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "5",
}